BRIEF-Sangamo Therapeutics Sangamo Says EMA Releases Details Supporting Orphan Designation For BIVV003 For Treatment Of Sickle Cell Disease

Reuters · 03/17/2021 20:42
BRIEF-Sangamo Therapeutics Sangamo Says EMA Releases Details Supporting Orphan Designation For BIVV003 For Treatment Of Sickle Cell Disease

- Sangamo Therapeutics Inc SGMO.O:

  • SANGAMO ANNOUNCES EMA RELEASES DETAILS SUPPORTING ORPHAN DESIGNATION FOR BIVV003 FOR TREATMENT OF SICKLE CELL DISEASE

Source text for Eikon: ID:nBwbX4XxRa

Further company coverage: SGMO.O


((Reuters.Briefs@thomsonreuters.com;))